Drug Approval | March 28, 2024
Biocon to obtain approval for diabetes drug, Liraglutide in UK
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Yesafili, received marketing authorization approval from the European Commission for the European Union
The company moves a step closer towards achieving its goal of emerging as the top oncology medicine supplier from India in the ASEAN region
With the combination of oral solid, inhalation, dermatology, high potent and oral contraceptive products, this is an important facility of the company
The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
Lutio has the potential to offer significant cost savings when available to UK patients.
Therapy recently approved in Canada under the brand name KORSUVA
The decision follows authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in May 2022.
PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
